Abstracts Archive - Page 86 of 2425 - ACR Meeting Abstracts

Abstract Number: 0435 • ACR Convergence 2024
Use of Contraception in Women of Childbearing Age with Immune-Mediated Rheumatic Diseases: Experience from an Italian Centre
Clizia Gagliardi¹, Maria Chiara Gerardi², Eleonora Giacobbe³, Sara Benedetti², Giuseppina Di Raimondo², Assunta Ascione³, Monica Barichello², Nicola Ughi⁴, Antonella Adinolfi², Laura Belloli², Cinzia Casu², Maria Di Cicco², Davide antonio Filippini², Matteo Longhi², Bianca Lucia Palermo², Martina Schettino², Giulia Segatto², Elisa Verduci² and Oscar Massimiliano Epis², ¹Niguarda Hospital, Milan, Bergamo, Italy, ²Niguarda Hospital, Milan, Milan, Italy, ³Niguarda Hospital, Milan, Milan, ⁴Niguarda Hospital, Milan, Mila, Italy
Background/Purpose: Contraception is a relevant issue for women of childbearing age with immune-mediated rheumatic diseases, as an unplanned pregnancy during active disease or treatment with…
Abstract Number: 0241 • ACR Convergence 2024
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
Rebecca Sadun¹, Dan Crair¹, Emmanuel Walter¹, Eugene St.Clair², David Pisetsky², Amanda Eudy³, Megan Clowse⁴, Jennifer Rogers⁵, Kai Sun¹, Lisa Criscione-Schreiber⁶, Mithu Maheswaranathan⁶, Jayanth Doss¹, Sarah Valencia¹ and M. Athony Moody⁷, ¹Duke University, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Duke University, Raleigh, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke University School of Medicine, Durham
Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
Abstract Number: 0551 • ACR Convergence 2024
Evaluation of Instruments Assessing Peripheral Arthritis in Spondyloarthritis: An Analysis of the ASAS-perSpA Study
Dafne Capelusnik¹, Anna Molto², Clementina López Medina³, Desiree van der Heijde⁴, Robert Landewé⁵, Maxime Dougados⁶, Joachim Sieper⁷ and Sofia Ramiro⁸, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Amsterdam University Medical Center, Meerssen, Netherlands, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The optimal instrument to assess peripheral arthritis and related disease activity in SpA has not yet been identified. In the recent update of the…
Abstract Number: 0545 • ACR Convergence 2024
Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
Stylianos Georgiadis¹, Marion Pons², Simon Horskjær Rasmussen², Merete Hetland³, Louise Linde², Daniela DiGuiseppe⁴, Brigitte Michelsen⁵, Johan Karlsson Wallman⁶, Tor Olofsson⁷, Karel Pavelka⁸, Jakub Závada⁸, Bente Glintborg⁹, Anne Gitte Loft¹⁰, Catalin Codreanu¹¹, Daniel Melim¹², Diogo Esperança Almeida¹³, Tore K. Kvien¹⁴, Vappu Rantalaiho¹⁵, Ritva Peltomaa¹⁶, Bjorn Gudbjornsson¹⁷, Olafur Palsson¹⁸, Ovidiu Rotariu¹⁹, Ross MacDonald¹⁹, Ziga Rotar²⁰, Katja Perdan-Pikmajer²⁰, Karin Laas²¹, Florenzo Iannone²², Adrian Ciurea²³, Mikkel Ostergaard²⁴ and Lykke Oernbjerg¹, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Glostrup, Denmark, ³Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁴Karolinska Institutet, Stockholm, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ⁷Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁸Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁹DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁰Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹¹University of Medicine and Pharmacy, Bucharest, Romania, ¹²Hospital Egas Moniz, Lisbon, Portugal, ¹³Hospital de Braga, Braga, Portugal, ¹⁴Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁵Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ¹⁶Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ¹⁷Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁸University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁹University of Aberdeen, Aberdeen, United Kingdom, ²⁰University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ²¹East-Tallinn Central Hospital, Tallinn, Estonia, ²²Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²³University Hospital Zurich, Zürich, Switzerland, ²⁴Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: In observational studies, several longitudinal methods have been proposed to impute missing data of an individual by using the available information of the same…
Abstract Number: 0560 • ACR Convergence 2024
Association Between a Self-Report Screening Tool for Sarcopenia (SARC-F) and Disease Activity, Muscle Strength and Muscle Power Measures, Patient-Reported Outcomes and Body Composition in Patients with Spondyloarthritides
Iuliia Kononenko¹, Marius Bedei², Bjoern Buehring³, Xenofon Baraliakos⁴ and Uta Kiltz⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Bochum, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Herne, Germany, ³Bergisches Rheuma-Zentrum, Wuppertal, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany
Background/Purpose: The SARC-F is a self-report screening tool for sarcopenia (Sar) used to identify individuals at risk for poor functional outcomes [1]. The aim of this study was…
Abstract Number: 0550 • ACR Convergence 2024
Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study
Nelly Ziade¹, Ihsane Hmamouchi², Clementina López Medina³, Maroun Aoun⁴, Sherif Gamal⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²International University of Rabat, Rabat, Morocco, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Saint Joseph University, Beirut, Lebanon, ⁵Cairo University, Cairo, Egypt, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…
Abstract Number: 0576 • ACR Convergence 2024
Less Than 15% Unfavourable Pregnancy Outcomes in Patients with Recent-onset Axial Spondyloarthritis: The Analysis of the 10 Years DESIR Cohort Follow-up
Madeleine FRANC¹, Anne Tournadre² and Anna Molto³, ¹Groupe Hospitalier Cochin, APHP, Paris, France, ²Service de Rhumatologie, centre hospitalier universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France, ³Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Only scarce data is available regarding pregnancy outcomes in early axSpA. The objective of this study was to determine (a) the factors associated with…
Abstract Number: 0591 • ACR Convergence 2024
Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Jessica A Walsh¹, Joseph F. Merola², Christopher T Ritchlin³, Yoshiya Tanaka⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jason Coarse⁹ and William Tillett¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²UT Southwestern Medical Center, Dallas, TX, ³Allergy, Immunology & Rheumatology Division, University of Rochester Medical School, Rochester, NY, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ⁶National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Morrisville, NC, ¹⁰Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic disease, and patients (pts) can experience loss of response with sustained therapy; therefore, assessing long-term maintenance of response in pts…
Abstract Number: 0596 • ACR Convergence 2024
Impact of a Multidisciplinary Rheumatology-Dermatology-Gastroenterology Center in the Management of Patients with Psoriatic Arthritis: Analysis of the First 5-years of Implementation
Marina Sánchez-Lucas¹, Camille Bourgeois¹, Juan Molina-Collada², Teresa Gonzalez-Hernandez¹, Juan Carlos Nieto Gonzalez¹, Amparo Lopez-Esteban¹, Ofelia Baniandres¹, Esther Chamorro de Vega¹ and Isabel Castrejon³, ¹Hospital Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) has a heterogenous clinical phenotype with manifestations in a number of different organs and systems. These include not only enthesitis, synovitis…
Abstract Number: 0554 • ACR Convergence 2024
Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
Carolina Merino¹, Zulema Plaza², Jordi Gratacos Masmitja³, Iago Rodríguez-Lago⁴, Elisa Trujillo⁵, Ignacio Marin-Jimenez⁶, Eva Perez Pampin⁷, Manuel Barreiro⁸, Vanesa Hernández-Hernández⁹, Marta Carrillo-Palau¹⁰, Maria Luz Garcia Vivar¹¹, Maria Carmen Muñoz¹², María Lourdes Ladehesa-Pineda¹³, Eva Iglesias Flores¹⁴, Yago González-Lama¹⁵, Marta Arevalo Salaet¹⁶, Xabier Calvet¹⁷, Ana Gutierrez-Casbas¹⁸ and JESUS SANZ SANZ¹⁹, and EISER group, ¹Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³University Hospital Parc Taulí, Sabadell, Spain, ⁴Gastroenterology department. Hospital Universitario Galdakao-Usansolo, Instituto de Investigación Sanitaria Biobizkaia, Galdakao, Bizkaia, Spain, Galdakao, Spain, ⁵Rheumatology department. Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ⁶Gastroenterology department. Hospital Universitario Gregorio Marañón, Madrid, Spain, ⁷Rheumatology department. Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Santiago de Compostela, Spain, ⁸Gastroenterology department. Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁹Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, ¹⁰Gastroenterology department. Hospital Universitario Canarias, La Laguna, Spain., Santa Cruz de Tenerife, Spain, ¹¹Basurto Hospital, Bilbao, Spain, ¹²Gastroenterology department. Hospital Universitario Basurto Hospital Universitario Basurto. Bilbao. Spain., Bilbao., Spain, ¹³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁴Gastroenterology department. Hospital Reina Sofia, Córdoba, Spain, Cordoba, Spain, ¹⁵Servicio de Gastroenterología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Spain, ¹⁶Parc Tauli Hospital Universitari I3PT, Rheumatology, Medicine Department, UAB, Sabadell, Spain, ¹⁷Gastroenterology department. Parc Taulí, Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Sabadell, Spain, Sabadell, Spain, ¹⁸Gastroenterology department. Hospital General Universitario de Dr. Balmis de Alicante. ISABIAL y CIBERehd, Alicante, Spain, Alicante, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: Axial spondyloarthritis (AxSpA) encompasses both non-radiographic axial spondyloarthritis (nr-AxSpA) and radiographic axial spondyloarthritis (r-AxSpA), also known as ankylosing spondylitis (AS). Although nr-AxSpA is often…
Abstract Number: 0569 • ACR Convergence 2024
The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort
Augusta Ortolan¹, Desiree van der Heijde², Laure Gossec³ and Sofia Ramiro⁴, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Lazio, Italy, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Sorbonne Université, Paris, France, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Health-related quality of life (HRQoL) in axSpA is considered an overarching outcome, with other disease outcomes contributing to it [1]. To validate a previously…
Abstract Number: 0565 • ACR Convergence 2024
Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
Anthony Lichaa¹, Pauline KRUG¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
Abstract Number: 0577 • ACR Convergence 2024
AMH Titers in Women with Axial Spondyloarthritis Are Significantly Lower Compared to the General Population: An Analysis of the 10-year Follow-up of the DESIR Cohort
Madeleine FRANC¹, Jean Guibourdenche², Anne Tournadre³ and Anna Molto⁴, ¹Groupe Hospitalier Cochin, APHP, Paris, France, ²Groupe Hospitalier Cochin, APHP, Paris, ³Service de Rhumatologie, centre hospitalier universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France, ⁴Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Data on fertility in women with spondyloarthritis (SpA) is sparse but seems to be impaired compared to the general population. Divergent results have been…
Abstract Number: 0588 • ACR Convergence 2024
Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
Laura Coates¹, Carlo Selmi², Philip Mease³, Alexis Ogdie⁴, Francois Nantel⁵, Frederic Lavie⁶, Mohamed Sharaf⁷, Oyediran Adelakun⁸, Emmanouil Rampakakis⁹, Laura Pina Vegas¹⁰ and Lihi Eder¹¹, ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Nantel MedSci Consult, Montreal, QC, Canada, ⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁷Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁸Janssen Research & Development, LLC, Titusville, NJ, ⁹McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Although PsA occurs in males and females at similar rates, clinical manifestations and outcomes differ between sexes. Findings from real-world evidence (RWE) studies have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].